Global Tricyclic antidepressants Market, By Drugs (Amitriptyline, Clomipramine, Doxepin, Imipramine, Trimipramine, Others), Indication (Major Depressive Disorder, Anxiety Disorders, Attention Deficit Hyperactivity Disorder, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Tricyclic antidepressants Market Analysis and Size
The global tricyclic antidepressants market is expected to witness significant growth during the forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market. Factors such as high prevalence of mental illness and presence of specialty centres are prominent factors that derive the global tricyclic antidepressants market.
Data Bridge Market Research analyses a growth rate in the global tricyclic antidepressants market in the forecast period 2022-2029. The expected CAGR of global tricyclic antidepressants market is tend to be around 7.80% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Tricyclic antidepressants, also called cyclic depressants, are a class of therapeutics that helps treat depression and other mental illness. The tricyclic antidepressants such as imipramine exert their action by inhibiting serotonin and norepinephrine uptake. It also suppresses the detrusor contraction and enhancing outlet resistance by urethral sphincter contraction.
Tricyclic antidepressants Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Amitriptyline, Clomipramine, Doxepin, Imipramine, Trimipramine, Others), Indication (Major Depressive Disorder, Anxiety Disorders, Attention Deficit Hyperactivity Disorder, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Mallinckrodt plc (U.K.), Sun Pharmaceutical Industries Ltd. (India), Novartis AG (Switzerland), Endo Pharmaceuticals plc (Ireland), Zydus Group (India), Mylan N.V. (U.S.), Mayne Pharma Group Limited (Australia), Teva Pharmaceutical Industries Ltd (Israel), Amneal Pharmaceutical Inc (U.S.), Avet Pharmaceuticals Inc. (U.S.), Aurobindo Pharma (India), Wockhardt (India), Currax Pharmaceuticals LLC (India)
|
|
Market Opportunities
|
|
Global Tricyclic antidepressants Market Dynamics
Drivers
- Rising Rates of Depression
Around 17.3 million people were suffering from major depressive episodes in the U.S. during 2017 as per the records of the National Institute of mental health (NIMH). The incidence rate is higher in adults aged 18 to 25 years. Hence, with high-stress conditions due to several socioeconomic factors and significant spending ability within this range, the segment is expected to flourish at a considerable rate during the forecast period.
- Increased Drug Launches
Rise in number of approvals for antidepressant drugs drive market growth. For instance, Food and Drug Administration (FDA) announced the approval of Tauvid in May 2020. It is an antidepressant drug used for the treatment of patients with Alzheimer disease.
Opportunities
- Technological Development
Increased technological development in the pharmaceutical industry to manufacture advanced tricyclic antidepressant drugs is expected to boost remunerative opportunities for expansion of the global tricyclic antidepressant drugs market during the forecast period 2022-2029. Additionally, presence of key manufacturing companies to develop antidepressant drugs boost growth of the market.
- Advanced Clinical Research
Increasing number of clinical trials leading to increasing novel drug approvals for treating antidepression will fuel the market expansion. Market leaders and government organizations are proactively involved in expanding product availability across the middle as well as low-income groups.
Restraints/Challenges
- Increased side effects
Several side effects associated with the consumption of tricyclic antidepressants such as feeling agitated, shaky or anxious, indigestion and stomach aches, diarrhoea or constipation, loss of appetite could curb the growth of the global tricyclic antidepressants market over a forecast period.
- High Cost
The huge expenditure required for developing the antidepressants surely hamper the market growth.
This global tricyclic antidepressants market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global tricyclic antidepressants market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Tricyclic antidepressants Market
Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period.
In the post-pandemic era, COVID-19 is expected to positively impact the global tricyclic antidepressants market, attributing to the increasing number of post-traumatic depressive symptoms among individuals.
Global Tricyclic antidepressants Market Scope
The global tricyclic antidepressants market is segmented on the basis of drugs, indication, route of administration, end-users, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Amitriptyline
- Clomipramine
- Doxepin
- Imipramine
- Trimipramine
- Others
Indication
- Major Depressive Disorder
- Anxiety Disorders
- Attention Deficit Hyperactivity Disorder
- Others
Route of Administration
- Oral
- Injectable
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Tricyclic antidepressants Market Regional Analysis/Insights
The global tricyclic antidepressants market is analysed and market size insights and trends are provided by drugs, indication, route of administration, end-users, distribution channel as referenced above.
The major countries covered in the global tricyclic antidepressants market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the global tricyclic antidepressants market due to the high demand for disease-specific treatment, the rise in adoption of newer technologies, the presence of refined healthcare expenditure, increased patient awareness, and the high prevalence of depressions.
Asia-Pacific is considered to have lucrative growth due to the presence of global marketed players in this region and growing cases of mental illness.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Tricyclic antidepressants Market Share Analysis
The global tricyclic antidepressants market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global tricyclic antidepressants market
Key players operating in the global tricyclic antidepressants market include:
- Mallinckrodt plc (U.K.)
- Sun Pharmaceutical Industries Ltd. (India)
- Novartis AG (Switzerland)
- Endo Pharmaceuticals plc (Ireland)
- Zydus Group (India)
- Mylan N.V. (U.S.)
- Mayne Pharma Group Limited (Australia)
- Teva Pharmaceutical Industries Ltd (Israel)
- Amneal Pharmaceutical Inc (U.S.)
- Avet Pharmaceuticals Inc. (U.S.)
- Aurobindo Pharma (India)
- Wockhardt (India)
- Currax Pharmaceuticals LLC (India)
SKU-